Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 63.99B |
| Revenue (ttm) | 14.09B |
| Net Income (ttm) | 4.50B |
| Shares Out | 105.67M |
| EPS (ttm) | 39.43 |
| PE Ratio | 15.36 |
| Forward PE | 16.85 |
| Dividend | $1.76 (0.29%) |
| Ex-Dividend Date | May 20, 2025 |
| Volume | 1,606,508 |
| Open | 601.12 |
| Previous Close | 590.00 |
| Day's Range | 601.12 - 612.68 |
| 52-Week Range | 525.99 - 1,211.20 |
| Beta | 0.43 |
| Analysts | Buy |
| Price Target | 907.39 (+49.83%) |
| Earnings Date | Apr 29, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price forecast is $907.39, which is an increase of 49.83% from the latest price.
News
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies 18 presentations across five cancer types include new insights on the...
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
24 abstracts, including 1 oral presentation and 4 late-breaking posters on Dupixent, to showcase new clinical and real-world analyses in chronic obstructive pulmonary disease (COPD) and asthma
Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides
On Tuesday, Regeneron Pharmaceuticals Inc REGN reported first-quarter adjusted earnings per share of $8.22, down 14% year-over-year, missing the consensus of $8.82.
Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Ryan Crowe - SVP, IR Leonard Schleifer - Board Co-Chair, Co-Founder, Pres...
Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More
U.S. equities were higher at midday as markets waited for further clarification from the Trump administration about possible changes in tariff policy. The Dow Jones Industrial Average rose 0.6%, and t...
Regeneron Stock Plummets After Earnings Miss
First-quarter adjusted earnings per share were $8.22 on revenue of $3 billion, missing analysts' expectations of EPS of $8.62 on revenue of $3.2 billion, according to FactSet.
Regeneron Pharma's first-quarter results miss on lower Eylea demand
Regeneron missed Wall Street estimates for first-quarter results on Tuesday, hurt by waning demand for its blockbuster eye disease drug Eylea, sending the company's shares tumbling 7% in premarket tra...
BMO's Evan Seigerman breaks down Pfizer and Regeneron's Q1 results
Evan David Seigerman, BMO head of healthcare research, joins 'Squawk Box' to break down Pfizer and Regeneron's quarter earnings results.
Regeneron Reports First Quarter 2025 Financial and Operating Results
TARRYTOWN, N.Y., April 29, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the first quarter of 2025 and provided a business update.
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
Approval of Lynozyfic is based on data showing deep and durable responses in relapsed/refractory multiple myeloma Lynozyfic will provide a new option with convenient dosing and administration to patie...
We're in a pharma stock pickers market, says Kessef's Len Yaffe
Len Yaffe, Kessef Capital Management, joins 'Fast Money' to talk opportunities in the pharma stock space.
Regeneron Expands US Manufacturing With $3 Billion Fujifilm Deal
Regeneron Pharmaceuticals, Inc. REGN on Tuesday announced a significant expansion of its manufacturing capacity through a new agreement with FUJIFILM Diosynth Biotechnologies to manufacture and suppl...
Regeneron signs over $3 billion deal with contract drugmaker to boost US manufacturing
Regeneron Pharmaceuticals said on Tuesday it had entered into a deal valued at more than $3 billion with contract drug developer Fujifilm Diosynth to expand its U.S. manufacturing capacity.
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron's biologic medicines and support high-paying jobs in the ...
FUJIFILM Diosynth Biotechnologies and Regeneron Sign a 10-Year U.S. Manufacturing Agreement Valued at Over $3 Billion
HOLLY SPRINGS, N.C.--(BUSINESS WIRE)-- #stemcells--FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced t...
Regeneron Announces Investor Conference Presentations
TARRYTOWN, N.Y., April 21, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:
LLY, NVO and AMGN Forecast – Pharma Stocks to Open Mixed
The three pharma stocks in this analysis all look a bit mixed in the premarket, after seeing some momentum late last week. This is especially true with LLY, as you will see on the charts.
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
TARRYTOWN, N.Y., April 18, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response lette...
Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition
The U.S. Food and Drug Administration approved the extended use of Sanofi and Regeneron's blockbuster drug Dupixent for patients with a type of skin condition, the two companies said on Friday.
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and...
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older...
Regeneron: Still A Biotech Juggernaut
Regeneron's stock has dropped 40% due to EYLEA's IP issues, but strong financials and pipeline assets bolster optimism for long-term growth. Dupixent's robust sales growth and potential new indication...
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...